BIONIK Laboratories Corp. Quarterly report pursuant to Section 13 or 15(d)

Warrants

9 Months Ended

Dec. 31, 2022

8. Warrants

The following is a continuity schedule of the Company’s common share purchase warrants:


		Weighted
		Average
	Number of	Exercise
	Warrants	Price
Outstanding and exercisable, March 31, 2021	122,367	$	19.69
Expired	(42,684)	$	(9.38)
Outstanding and exercisable, March 31, 2022	79,683	$	25.22
Expired	(64,025)		(9.38)
Outstanding and exercisable December 31, 2022	15,658	$	90.00

The following is a summary of common share purchase warrants outstanding as of December 31, 2022.

The weighted-average remaining contractual term of the outstanding warrants was 0.25 years.